Eosinophilic Esophagitis and Proton Pump-Responsive Esophageal Eosinophilia: What Is in a Name?

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 12, 2014, Pages 2023-2025

  Katzka, David A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 15 LIPOXYGENASE; AZATHIOPRINE; EOSINOPHIL PEROXIDASE; EOTAXIN 3; INTERLEUKIN 13; INTERLEUKIN 5; OMEPRAZOLE; PROTON PUMP INHIBITOR; STAT6 PROTEIN; STEROID; TRYPTASE; BIOLOGICAL MARKER;

CYTOKINE RELEASE; EDITORIAL; EOSINOPHIL COUNT; EOSINOPHILIC ESOPHAGITIS; ESOPHAGUS DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; MAST CELL; PROTON PUMP RESPONSIVE ESOPHAGEAL EOSINOPHILIA; CHEMICALLY INDUCED; EOSINOPHILIA; FEMALE; MALE; PROCEDURES;

BIOLOGICAL MARKERS; EOSINOPHILIA; EOSINOPHILIC ESOPHAGITIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROTON PUMP INHIBITORS;

EID: 84918768543     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.07.035     Document Type: Editorial

References (24)

1. Molina-Infante J., Ferrando-Lamana A., Ripoll C., et al. Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults. Clin Gastroenterol Hepatol 2011, 9:110-117.
2. Francis D.L., Foxx-Orenstein A., Arora A.S., et al. Results of ambulatory pH monitoring do not reliably predict response to therapy in patients with eosinophilic esophagitis. Aliment Pharmacol Ther 2012, 35:300-307.
3. Dellon E.S., Speck O., Woodward K., et al. Clinical and endoscopic characteristics do not reliably differentiate PPI-responsive esophageal eosinophilia and eosinophilic esophagitis in patients undergoing upper endoscopy: a prospective cohort study. Am J Gastroenterol 2013, 108:1854-1860.
4. Vazquez-Elizondo G., Ngamruengphong S., Khrisna M., et al. The outcome of patients with esophageal eosinophilic infiltration after an eight-week trial of a proton pump inhibitor. Aliment Pharmacol Ther 2013, 38:1312-1319.
5. Martinek J., Strosova A., Stefanova M., et al. Treatment with proton pump inhibitors is effective in a majority of adults patients with eosinophilic esophagitis. Gastroenterology 2013, 144(Suppl 1). S-493.
6. Molina-Infante J., Katzka D.A. Proton-pump inhibitor-responsive esophageal eosinophilia. Curr Opin Gastroenterol 2014, 30:428-433.
7. Dellon E.S., Speck O., Woodward K., et al. Markers of eosinophilic inflammation for diagnosis of eosinophilic esophagitis and proton pump inhibitor-responsive esophageal eosinophilia: a prospective study. Clin Gastroenterol Hepatol 2014, 12:2015-2022.
8. Blanchard C., Wang N., Stringer K.F., et al. Eotaxin-3 and a uniquely conserved gene expression profile in eosinophilic esophagitis. JClin Invest 2006, 116:536-547.
9. Abonia J.P., Blanchard C., Butz B.B., et al. Involvement of mast cells in eosinophilic esophagitis. JAllergy Clin Immunol 2010, 126:140-149.
10. Sridhara S., Ravi K., Smyrk T.C., et al. Increased numbers of eosinophils, rather than only etiology, predict histologic changes in patients with esophageal eosinophilia. Clin Gastroenterol Hepatol 2012, 10:735-741.
11. Blanchard C., Stucke E.M., Rodriguez-Jimenez B., et al. Astriking local esophageal cytokine expression profile in eosinophilic esophagitis. JAllergy Clin Immunol 2011, 127:208-217. 217 e1-7.
12. Molina-Infante J., Rivas M.D., Rodriguez G.V., et al. Remission in proton pump inhibitors-responsive esophageal eosinophilia correlates with downregulation of eotaxin-3 and Th2 cytokines, similarly to eosinophilic esophagitis after steroids. Gastroenterology 2014, 146(Suppl). S-484.
13. Matoso A., Allen D., Herzlinger M., et al. Correlation of ALOX15 expression with eosinophilic or reflux esophagitis in a cohort of pediatric patients with esophageal eosinophilia. Hum Pathol 2014, 45:1205-1212.
14. Protheroe C., Woodruff S.A., de Petris G., et al. Anovel histologic scoring system to evaluate mucosal biopsies from patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol 2009, 7:749-755.
15. Dohil R., Newbury R.O., Aceves S. Transient PPI responsive esophageal eosinophilia may be a clinical sub-phenotype ofpediatric eosinophilic esophagitis. Dig Dis Sci 2012, 57:1413-1419.
16. Cheng E., Zhang X., Huo X., et al. Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic esophagitis and GORD. Gut 2013, 62:824-832.
17. Souza R.F., Huo X., Vittal M., et al. Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury. Gastroenterology 2009, 137:1776-1784.
18. Zhang X., Cheng E., Huo X., et al. Omeprazole blocks STAT6 binding to the eotaxin-3 promoter in eosinophilic esophagitis cells. PLoS One 2012, 7:e50037.
19. van Rhjin B.D., Weijenborg P.W., Verheij J., et al. Proton pump inhibitors partially restore mucosal integrity in patients with PPI-responsive esophageal eosinophilia but not eosinophilic esophagitis. Clin Gastroenterol Hepatol 2014 Mar 19, Epub ahead of print.
20. Alexander J.A., Jung K.W., Arora A.S., et al. Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis. Clin Gastroenterol Hepatol 2012, 10:742-749.
21. Wen T., Stucke E.M., Grotjan T.M., et al. Molecular diagnosis of eosinophilic esophagitis by gene expression profiling. Gastroenterology 2013, 145:1289-1299.
22. Dellon E.S. Diagnosis and management of eosinophilic esophagitis. Clin Gastroenterol Hepatol 2012, 10:1066-1078.
23. William Shakespeare. Romeo and Juliet. Act II, Scene II,1594.
24. Gertrude Stein Sacred Emily, geography and plays 1993, University of Wisconsin Press, Madison, WI.